Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 13/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PDE7A | Q13946 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13668648 | 0.90 | — | — | |
| SCHEMBL14401968 | 0.81 | CTSL (0.35) | PDE4A | |
| SCHEMBL27643350 | 0.80 | PDE4A (0.30) | PDE4A | |
| SCHEMBL14401966 | 0.80 | DPP4 (0.32) | PDE4A | |
| SCHEMBL16846923 | 0.78 | PDE4A (0.33) | PDE4A | |
| SCHEMBL27283730 | 0.77 | PDE4A (0.34) | PDE4ACYP1A2GAAPDE7A | |
| SCHEMBL7744910 | 0.77 | PDE4A (0.35) | PDE4ACYP1A2GAAPDE7AALDH1A1 | |
| SCHEMBL15229352 | 0.76 | PDE4A (0.37) | PDE4ACYP1A2GAAPDE7AKDM4E | |
| SCHEMBL3330295 | 0.74 | MEN1 (0.44) | PDE4A | |
| SCHEMBL26883500 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150299120-A1 | Spirohydantoin compounds and their use as selective androgen receptor modulators | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-10-22 | — | — | US | disclosed |
| US-20150299120-A1 | Spirohydantoin compounds and their use as selective androgen receptor modulators | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-10-22 | — | — | US | disclosed |
| US-20150299120-A1 | Spirohydantoin compounds and their use as selective androgen receptor modulators | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-10-22 | — | — | US | disclosed |
| US-20150148344-A1 | QUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. | 2015-05-28 | — | — | US | disclosed |
| EP-2819999-A1 | SPIROHYDANTOIN COMPOUNDS AND THEIR USE AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | Novartis AG (CH) | 2015-01-07 | — | — | EP | disclosed |
| WO-2013128421-A1 | SPIROHYDANTOIN COMPOUNDS AND THEIR USE AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013128421-A1 | SPIROHYDANTOIN COMPOUNDS AND THEIR USE AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2013-09-06 | — | — | WO | disclosed |
| US-8129423-B2 | 1-Adamantan-2-yl-3-benzyl-1,3-dihydro-imidazol-2-one; 11beta-hydroxysteroid dehydrogenases (11beta-HSD) inhibitor; antidiabetic, hypotensive, hypoglycemic agent; resist hyperglycemia provoked by obesity or stress; | HOFFMAN-LA ROCHE INC. (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2308851-A1 | Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors for the treatment of diabetes | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| EP-2104665-A2 | IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS FOR DIABETES | F. Hoffmann-Roche AG (CH) | 2009-09-30 | — | — | EP | disclosed |
| US-20080103183-A1 | NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
| WO-2008046758-A2 | IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS FOR DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148344-A1 | QUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD7, BRD3 | PDE4A 3106/4885CYP1A2 3706/4885GAA 4399/4885 |
| US-20080103183-A1 | NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HSD11B1, HSD17B1, HSD17B11 | PDE4A 487/4885CYP1A2 67/4885GAA 3162/4885 |
| US-20150299120-A1 | Spirohydantoin compounds and their use as selective androgen receptor modulators | NR5A1, AR, SRD5A1 | PDE4A 572/4885CYP1A2 196/4885GAA 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.